A Long Overdue Targeted Treatment for KRAS Mutations in NSCLC: Spotlight on Adagrasib

References

• American Cancer Society. Cancer facts and figures 2021; 2021. Available from: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2021/cancer-facts-and-figures-2021.pdf. Accessed October 21, 2022.
   Google Scholar
• Imielinski M, Berger A, Hammerman P, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 2012;150(6):1107–1120. doi:10.1016/j.cell.2012.08.029
   PubMed Web of Science ®Google Scholar
• Lee B, Lee T, Lee SH, et al. Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6595 lung cancers. Oncotarget. 2016;7(17):23874–23884. doi:10.18632/oncotarget.8074
   PubMedGoogle Scholar
• Fernández-Medarde A, Santos E. Ras in cancer and developmental diseases. Genes Cancer. 2011;2(3):344–358. doi:10.1177/1947601911411084
   PubMedGoogle Scholar
• Tímár J. The clinical relevance of KRAS gene mutation in non-small-cell lung cancer. Curr Opin Oncol. 2014;26(2):138–144. doi:10.1097/CCO.0000000000000051
   PubMed Web of Science ®Google Scholar
• Dearden S, Stevens J, Wu Y-L, et al. Mutation incidence and coincidence in non small-cell lung cancer, meta-analyses by ethnicity and histology (mutMap). Ann Oncol. 2013;24(9):2371–2376. doi:10.1093/annonc/mdt205
   PubMed Web of Science ®Google Scholar
• Yang H, Liang S-Q, Schmid RA, et al. New Horizons in KRAS-mutant lung cancer, dawn after darkness. Front Oncol. 2019;9:953. doi:10.3389/fonc.2019.00953
   PubMed Web of Science ®Google Scholar
• Matikas A, Mistriotis D, Georgoulias V, et al. Targeting KRAS mutated non-small cell lung cancer, A history of failures and a future of hope for a diverse entity. Crit Rev Oncol Hematol. 2017;110:1–12. doi:10.1016/j.critrevonc.2016.12.005
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Domerg C, Hainaut P, et al. Pooled analysis of the prognostic and predictive effects of KRAS mutation status and kras mutation subtype in early-stage resected non–small-cell lung cancer in four trials of adjuvant chemotherapy. J Clin Oncol. 2013;31(17):2173–2181. doi:10.1200/JCO.2012.48.1390
   PubMed Web of Science ®Google Scholar
• Redig AJ, Chambers ES, Lydon CA, et al. Genomic complexity in KRAS mutant non-small cell lung cancer (NSCLC) from never/light-smokers v smokers. J Clin. 2016;34(15_suppl):9087. doi:10.1200/JCO.2016.34.15_suppl.9087
   Google Scholar
• Ferrer I, Zugazagoitia J, Herbertz S, et al. KRAS-Mutant non-small cell lung cancer, From biology to therapy. Lung Cancer. 2018;124:53–64. doi:10.1016/j.lungcan.2018.07.013
   PubMed Web of Science ®Google Scholar
• Mascaux C, Iannino N, Martin B, et al. The role of RAS oncogene in survival of patients with lung cancer, a systematic review of the literature with meta-analysis. Br J Cancer. 2005;92(1):131–139. doi:10.1038/sj.bjc.6602258
   PubMed Web of Science ®Google Scholar
• Jacobs F, Cani M, Malapelle U, et al. Targeting KRAS in NSCLC, old failures and new options for “Non-G12c”Patients. Cancers. 2021;13(24):6332. doi:10.3390/cancers13246332
   PubMed Web of Science ®Google Scholar
• Nassar AH, Adib E, Kwiatkowski DJ. Distribution of KRASG12C somatic mutations across race, sex, and cancer type. N Engl J Med. 2021;384(2):185–187. doi:10.1056/NEJMc2030638
   PubMed Web of Science ®Google Scholar
• Salem M, El-Refai S, Sha W, et al. O-3 Characterization of KRAS mutation variants and prevalence of KRAS-G12C in gastrointestinal malignancies. Ann Oncol. 2021;32:S218. doi:10.1016/j.annonc.2021.05.007
   PubMed Web of Science ®Google Scholar
• Ou SH, Jänne PA, Leal TA, et al. First-in-human phase I/IB dose-finding study of adagrasib (MRTX849) in patients with advanced KRASG12C solid tumors (KRYSTAL-1). J Clin. 2022;40(23):2530.
   Google Scholar
• Finn SP, Addeo A, Dafni U, et al. Prognostic impact of KRAS G12C mutation in patients with NSCLC, results from the European thoracic oncology platform lungscape project. J Thorac Oncol. 2021;16(6):990–1002. doi:10.1016/j.jtho.2021.02.016
   PubMed Web of Science ®Google Scholar
• Wu MY, Zhang EW, Strickland MR, et al. Clinical and imaging features of non-small cell lung cancer with G12C KRAS mutation. Cancers. 2021;3(14):3572.
   Web of Science ®Google Scholar
• Cui W, Franchini F, Alexander M, et al. Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer. Lung Cancer. 2020;146:310–317. doi:10.1016/j.lungcan.2020.06.030
   PubMed Web of Science ®Google Scholar
• Tomasini P, Serdjebi C, Khobta N, et al. EGFR and KRAS mutations predict the incidence and outcome of brain metastases in non-small cell lung cancer. Int J Mol Sci. 2016;17(12):2132. doi:10.3390/ijms17122132
   PubMed Web of Science ®Google Scholar
• Dang CV, Reddy EP, Shokat KM, et al. Drugging the ‘undruggable’ cancer targets. Nat Rev Cancer. 2017;17(8):502–508. doi:10.1038/nrc.2017.36
   PubMed Web of Science ®Google Scholar
• Lindsay CR, Jamal-Hanjani M, Forster M, et al. KRAS, Reasons for optimism in lung cancer. Eur J Cancer. 2018;99:20–27. doi:10.1016/j.ejca.2018.05.001
   PubMed Web of Science ®Google Scholar
• Ostrem JM, Peters U, Sos ML, et al. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature. 2013;503(7477):548–551. doi:10.1038/nature12796
   PubMed Web of Science ®Google Scholar
• Hallin J, Engstrom LD, Hargis L, et al. The KRAS(G12C) Inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients. Cancer Discov. 2020;10(1):54–71. doi:10.1158/2159-8290.CD-19-1167
   PubMed Web of Science ®Google Scholar
• Nakajima EC, Drezner N, Li X, et al. FDA approval summary: sotorasib for KRAS G12C -mutated metastatic NSCLC. Clin Cancer Res. 2022;28(8):1482–1486. doi:10.1158/1078-0432.CCR-21-3074
   PubMed Web of Science ®Google Scholar
• Fell JB, Fischer JP, Baer BR, et al. Identification of the clinical development candidate MRTX849, a covalent KRAS G12C inhibitor for the treatment of Cancer. J Med Chem. 2020;63(13):6679–6693. doi:10.1021/acs.jmedchem.9b02052
   PubMed Web of Science ®Google Scholar
• Riely GJ, Ou S-HI, Rybkin I, et al. 99O_PR KRYSTAL-1, Activity and preliminary pharmacodynamic (PD) analysis of adagrasib (MRTX849) in patients (Pts) with advanced non–small cell lung cancer (NSCLC) harboring KRASG12C mutation. J Thorac Oncol. 2021;16(4):S751–S752. doi:10.1016/S1556-0864(21)01941-9
   Web of Science ®Google Scholar
• Janne PA, Papadopoulos K, Ou I, et al. A phase 1 clinical trial evaluating the pharmacokinetics (PK), safety, and clinical activity of MRTX849, a mutant-selective small molecule KRAS G12C inhibitor, in advanced solid tumors. AACR-NCI-EORTC International Conference on Molecular Targets; Boston, MA, USA; 2019.
   Google Scholar
• Jänne PA, Riely GJ, Gadgeel SM, et al. Adagrasib in non–small-cell lung cancer harboring a KRAS G12C mutation. N Engl J Med. 2022;387:120–131. doi:10.1056/NEJMoa2204619
   PubMed Web of Science ®Google Scholar
• Sabari JK, Velcheti V, Shimizu K, et al. Activity of Adagrasib (MRTX849) in brain metastases, preclinical models and clinical data from patients with KRASG12C-mutant non–small cell lung cancer. Clin Cancer Res. 2022;28(15):3318–3328.
   PubMed Web of Science ®Google Scholar
• Skoulidis F, Li BT, Dy GK, et al. Sotorasib for Lung Cancers with KRAS p.G12C Mutation. N Engl J Med. 2021;384(25):2371–2381. doi:10.1056/NEJMoa2103695
   PubMed Web of Science ®Google Scholar
• Nagasaka M, Azmi AS. Clinical progress of KRAS-targeted therapies, what next? Future Med Chem. 2022;14(15):1107–1110.
   PubMed Web of Science ®Google Scholar
• Awad MM, Liu S, Rybkin II, et al. Acquired resistance to KRAS G12C inhibition in cancer. N Engl J Med. 2021;384(25):2382–2393. doi:10.1056/NEJMoa2105281
   PubMed Web of Science ®Google Scholar
• Tanaka N, Lin JJ, Li C, et al. Clinical acquired resistance to KRAS(G12C) Inhibition through a novel KRAS switch-II pocket mutation and polyclonal alterations converging on RAS-MAPK reactivation. Cancer Discov. 2021;11(8):1913–1922. doi:10.1158/2159-8290.CD-21-0365
   PubMed Web of Science ®Google Scholar
• Koga T, Suda K, Fujino T, et al. KRAS secondary mutations that confer acquired resistance to KRAS G12C inhibitors, sotorasib and adagrasib, and overcoming strategies insights from in vitro experiments. J Thorac Oncol. 2021;16(8):1321–1332. doi:10.1016/j.jtho.2021.04.015
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhang F, Niu R. Functions of Shp2 in cancer. J Cell Mol Med. 2015;19(9):2075–2083. doi:10.1111/jcmm.12618
   PubMed Web of Science ®Google Scholar